SecBot SecBot
8-K ·Filed Jul 20, 2026

ARMP

Armata Pharmaceuticals, Inc.
BULLISH
Impact 5/10
Horizonmonths Processed3mo ago SEC0001104659-26-084861
Actionable Insight ▲ Bullish

The clinical progress is a positive step but the real catalyst will be the initiation of the Phase 3 study and eventual data readout. Monitor for Phase 3 start in H2 2026 and any additional funding announcements. The CFO promotion is routine and does not change the investment thesis.

DirectionBullish
Confidencemedium
Horizonmonths

AP-SA02

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2 complete; Phase 3 (registrational) planned for H2 2026
Time to market
Phase 3 (registrational) initiation expected H2 2026; pivotal data and any BLA/approval are realistically 2028-2030 at the earliest, contingent on Phase 3 success — AP-SA02 is years from commercialization.
Next catalyst
None dated

What to watchWatch for confirmation of the Phase 3 start (H2 2026 window) and any financing announcement, because the ~$5.07 stock's biggest near-term risks are cash runway and dilution, not trial mechanics. The real share-price binary, Phase 3 topline data, is likely 2+ years out, so treat the gap between the stock and the ~$17.5 mean analyst target as a long-dated optionality play, not a near-term event.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$5.06
T+0 close · Jul 20, 2026 · via day close
Latest settled
−38.74%
T+60 · $3.10
Vs SPY
−43.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 20 $5.06entry
  2. T+1 · 4mo ago +1.98%α +1.14% · $5.16
  3. T+5 · 4mo ago −7.91%α −7.48% · $4.66
  4. T+20 · 3mo ago −11.46%α −15.58% · $4.48
  5. T+60 · 5w ago −38.74%α −43.58% · $3.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Armata Pharmaceuticals announced clinical, regulatory, and manufacturing progress for its lead candidate AP-SA02, including submission of the Phase 3 protocol to the FDA and completion of four engineering runs, keeping the Phase 3 superiority study on track for H2 2026. The company also disclosed a $2.5 million DoD award continuation (total $28.7M) and promoted David House to CFO. The clinical update is a positive catalyst but the company remains pre-revenue with no financial results reported.

Key Facts

  • Phase 3 superiority protocol for AP-SA02 submitted to FDA; all End-of-Phase 2 meeting comments addressed.
  • Four engineering runs of AP-SA02 completed; clinical trial material production is the next manufacturing step.
  • Phase 3 study remains on track to initiate in the second half of 2026.
  • DoD award continuation of $2.5 million brings total funding under the award to $28.7 million.
  • David House promoted to CFO with base salary of $371,315, target bonus of 50%, and annual equity award intent of ~$300,000.

Financial Impact

No revenue or earnings reported. The DoD award provides $2.5M in additional non-dilutive funding, bringing total DoD support to $28.7M. The company is pre-revenue and will require additional capital to fund the Phase 3 study.

Risk Factors

  • Clinical trial risk: Phase 3 may fail to meet endpoints.
  • Funding risk: Company needs additional capital to execute Phase 3 study beyond existing DoD award.
  • Regulatory risk: FDA may require additional data before accepting BLA.

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 11 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (ARMP), Batch item 10001104659-26-084861
Document: tm2620782d2_ex99-1.htm0001104659-26-084860
Document: 0001104659-26-084861-index-headers.html0001104659-26-084861
Document: 0001104659-26-084861-index.html0001104659-26-084861
Document: 0001104659-26-084861.txt0001104659-26-084861
8-K Filing (ARMP), Batch item 60001104659-26-084860
Document: tm2620782d1_8k.htm0001104659-26-084861
Document: tm2620782d1_ex10-2.htm0001104659-26-084861
Document: 0001104659-26-084860-index-headers.html0001104659-26-084861
Document: 0001104659-26-084860-index.html0001104659-26-084861
Document: 0001104659-26-084860.txt0001104659-26-084861

Track record

6 reports on ARMP

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +43.90% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $3.87 Now $2.99 −22.74% settles Dec 14
  2. Sep 23, 20267w ago 8-K Bullish 5/10 Entry $3.64 to $3.06 Now $2.99 −17.86% ▼ −15.93% −16.62% vs SPY
  3. Sep 14, 20269w ago 8-K Bullish 7/10 Entry $5.55 to $3.63 Now $2.99 −46.13% ▼ −34.59% −36.86% vs SPY
  4. Jul 20, 202617w ago 8-K Bullish 5/10 Viewing Entry $5.06 to $4.48 Now $2.99 −40.91% ▼ −11.46% −15.58% vs SPY
  5. May 13, 202626w ago 8-K Bearish 6/10 Entry $8.20 to $7.58 Now $2.99 +63.54% ▲ +7.56% +6.70% vs SPY
  6. Apr 27, 202629w ago 8-K Neutral 3/10 Entry $11.00 to $8.17 Now $2.99 −72.82% ▼ −25.73% −30.68% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 9h 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026